Published in Oncology Business Week, July 2nd, 2006
Genentech has requested Priority Review of the application, which means that if accepted, the FDA would make its decision on the application within six months of the agency's receipt of the submission, or in November 2006. Avastin is currently approved as a first-line treatment for metastatic colorectal cancer in combination with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week